Generated by AI
TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies and immuno-oncology programs for high-risk and advanced cancers. The company’s current work centers on targeted cancer therapeutics designed to address metastatic disease, including candidates that modulate microRNA pathways and other genetic mechanisms linked to tumor growth and spread. Its pipeline also includes programs exploring RNA delivery platforms and combination approaches aimed at improving how nucleic-acid medicines reach cancer cells. TransCode Therapeutics operates within the oncology and RNA therapeutics segments of the life sciences market, where it contributes to the development of precision treatments for difficult-to-treat malignancies. Headquartered in Boston, Massachusetts, the company concentrates on advancing experimental cancer therapies through clinical and preclinical development.
Website6 Liberty Square
Boston, MA, 02109
United States
The latest articles about RNAZ.
--TransCode Therapeutics, Inc., a clinical-stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, released its poster 1025 P describing the clinical results from its Phase 1 a clinical trial of TTX-MC138 at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.
Detailed price information for Transcode Therapeutics Inc (RNAZ-Q) from The Globe and Mail including charting and trades.
Summary of Aug 31's posts. Generated by AI.
Summary of Jun 3's posts. Generated by AI.
Summary of Feb 9's posts. Generated by AI.
Investors talking about RNAZ also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.